Silence Therapeutics plc 8-K/A

What Happened

• Silence Therapeutics plc (filed 8-K dated Dec 22, 2025, Item 5.02) announced that Iain Ross, Chairman of the Board, was appointed interim principal executive officer effective December 14, 2025. On December 18, 2025, the Board approved his compensation: monthly cash pay and an equity option grant. The filing also updates board appointments for James Ede-Golightly and related compensation.

Key Details

• Interim CEO pay: £25,000 GBP per month for six months starting with the appointment; thereafter month-to-month by mutual agreement.
• Interim CEO bonus: potential cash bonus at the sole discretion of the Remuneration Committee.
• Iain Ross equity: option to purchase 900,000 ordinary shares under the 2023 Equity Incentive Plan, vesting equally over 12 months.
• Director appointment and equity: James Ede-Golightly appointed to Remuneration, Audit & Risk, and Nominations Committees (effective Dec 18, 2025) and granted an option to purchase 90,000 ordinary shares, vesting equally over 12 months.
• Corporate housekeeping: No family relationships or reportable related-party transactions were disclosed in connection with Ross’s appointment.

Why It Matters

• Leadership: Naming an interim CEO is material for investors because it affects executive leadership and strategy execution until a permanent CEO is appointed.
• Compensation & dilution: The cash payments and option grants create near-term compensation expense and could lead to share dilution if options are exercised; the relatively fast 12-month vesting accelerates potential impact.
• Governance: Ede-Golightly’s committee assignments affect oversight of pay, audit/risk and nominations, which may influence governance and executive compensation decisions.
• Disclosure: The filing provides concrete, non-speculative facts investors can use to assess management stability, potential dilution, and governance changes.